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ess: t.hansel@ic.ac.ukSummary Inhaled corticosteroids (ICSs) are the gold standard anti-inflammatory
therapy for asthma and have been studied using a variety of different clinical trial
designs. In long-term comparative studies ICSs are more effective in controlling
asthma than b-agonists or leukotriene antagonists (LTAs). Efficacy has also been
shown retrospectively, as patients frequently experience an exacerbation of their
asthma upon withdrawal of ICSs, whilst the regular use of low dose ICSs prevents
death from asthma. The combination of ICSs with long-acting b2-agonists (LABAs) is
effective for patients with asthma non-responsive to low doses of ICSs, particularly
in reducing exacerbations. In shorter term studies a modest dose–response effect of
ICSs has been shown for lung function, symptom control and oral corticosteroid use
in asthmatic patients. ICSs are also effective in reducing airway hyperresponsiveness
(AHR) to various stimuli, as well as reducing exhaled nitric oxide (NO) concentrations
and the number and activation state of a wide variety of inflammatory cells. Finally,
using allergen challenge models even single doses of ICSs have profound inhibitory
effects on the late asthmatic reaction. Since ICSs are the mainstay of asthma
management guidelines, it is important that novel therapies should be judged
against ICSs in future clinical trials. There are many potential designs for these
comparative studies.
r 2004 Elsevier Ltd. All rights reserved.4 Elsevier Ltd. All rights reserv
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(T.T. Hansel).Introduction
Inhaled corticosteroids (ICSs) are recommend as
first line therapy for all asthmatic patients with
persistent symptoms and are the most effective
therapy currently available for the treatment of
asthma. They have revolutionised asthma treat-
ment and have become the mainstay of therapy for
patients with chronic disease. Clinically, ICSs are
very effective in controlling asthma symptoms ined.
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T.T. HanselS10patients of all ages and severity. They improve lung
function and quality of life, reduce the frequency
of exacerbations and may prevent irreversible
airway changes. The effectiveness of corticoster-
oids is based on the fact that they have a wide
spectrum of anti-inflammatory action, reducing the
number and activation state of many cells involved
in the underlying inflammation of asthma. The aim
of this review is to assess the various clinical trial
designs used to determine the efficacy of ICSs in
asthma.Comparative studies
A simple way to assess the efficacy of ICSs is to
compare their effect(s) with other agents com-
monly prescribed to treat asthma. In the following
section the efficacy of ICSs is compared to that of
inhaled b2-agonists, or leukotriene antagonists
(LTAs).
Inhaled corticosteroid versus inhaled b2-
agonist
Haahtela and colleagues1 compared the effect of
an ICS, budesonide (600 mg bd), and an inhaled b2-
agonist, terbutaline (375 mg bd), in the long-term
management (2 years) of patients with newly
detected asthma (n ¼ 103). The study showed that
budesonide was more effective than terbutaline in
improving airway hyperresponsiveness (AHR) to
histamine and improving morning and evening peak
expiratory flow (PEF) (Fig. 1), and more effective in
reducing asthma symptoms and use of rescue
medication.1 A follow-up biopsy study of 3 months
duration using the same concentrations of budeso-
nide and terbutaline in 14 patients with newly
diagnosed asthma showed that budesonide was500
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Figure 1 Long-term treatment with budesonide
(600 mg bd) is more effective than terbutaline (375 mg bd)
in improving morning peak expiratory flow (PEF) in
patients with newly detected asthma (n ¼ 103). Rep-
rinted with permission from Haahtela et al.1more effective than terbutaline in ameliorating
abnormalities of the bronchial epithelium and
decreasing inflammation in the airways.2 In parti-
cular, patients treated with budesonide had in-
creased numbers of ciliated airway cells and
intraepithelial nerves, as well as fewer inflamma-
tory cells (including eosinophils) especially in the
epithelium.2
Inhaled corticosteroid versus leukotriene
antagonist
Bukstein and colleagues3 evaluated the efficacy of
oral montelukast and inhaled fluticasone propio-
nate (FP) in a randomised, prospective 12-month
‘real-world’ observational analysis of children
(6–15 years) with mild persistent asthma. The
results of this study suggested that oral montelu-
kast and inhaled FP have similar ‘real-world’
efficacies in the treatment of these patients,
possibly as a result of the significantly better
adherence to oral montelukast therapy. In general,
ICS are much more effective than LTAs in asthma
trials, ICS usually causing about double the im-
provement in lung function than found with LTAs.
However, in adults with persistent asthma, long-
term treatment with low dose FP was more
effective than oral montelukast as first-line main-
tenance therapy.4,5 Similarly, in a short-term study,
steroid-naı¨ve patients with moderate asthma trea-
ted with either montelukast (10mg, once a day) or
low-dose inhaled FP (100 mg bd) had comparable
bronchodilator action, but those treated with FP
showed additional attenuation of airway inflamma-
tion as evidenced by reduced exhaled nitric oxide
(NO) and eosinophils in induced sputum.6Additive therapy
The efficacy of ICSs can be observed when added to
another agent used to treat asthma. Results from
clinical studies using non-fixed combinations of ICSs
and LABAs (i.e. delivered via separate inhalers)
have demonstrated that the addition of a long-
acting b2-agonist (LABA) to an ICS is associated with
statistically and clinically significant improvements
in both objective and subjective measures of
asthma control relative to the administration of
higher doses of ICS.7,8 Results from a systematic
review 9 showed that the addition of salmeterol in
patients taking low-to-moderate doses of ICSs gave
improved lung function (PEF and FEV1) and in-
creased the number of days and nights without
symptoms or need for rescue treatment with no
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Effectiveness of inhaled corticosteroids S11increase in exacerbations of any severity. Similarly,
a one year study in 852 patients with asthma
showed that the addition of formoterol (12 mg) to
budesonide (100 or 400 mg) caused a dose-depen-
dent reduction in the rate of both mild and severe
exacerbations compared to budesonide alone.10
Combination therapy with salmeterol and ICSs in
patients with persistent asthma provided signifi-
cantly greater improvement in overall asthma
control than oral zafirlukast 11 or oral montelukast
therapy.12
ICSs and LABAs are also available as a combina-
tion product delivered by a single inhaler at fixed
dosages. Although, ICS/LABA combinations suit
selected asthmatic patients, the fixed-dose nature
of the combination reduces the flexibility of
treatment and challenges the step care approach
advocated by current National Institutes of Health
(NIH) guidelines. It is essential that medication can
be easily added and dosages of controller medica-
tion increased as disease severity increases. Con-
versely, once symptoms subside the step care
approach recommends gradual reduction of con-
troller medication dose and cessation of add-on
therapies. Non-fixed combination products provide
physicians and patients with greater flexibility.Steroid tapering
Discontinuation of corticosteroid therapy allows
the retrospective examination of ICS efficacy in
asthmatic patients. In a follow up study to their
1991 study, Haahtela and colleagues13 showed that
early treatment with inhaled budesonide resulted
in long-lasting control of mild asthma. Maintenance
therapy could be given at a reduced dose (400 mg/
day), but discontinuation of treatment was often380 
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Figure 2 Discontinuation of inhaled budesonide therapy caus
patients with mild asthma. Reprinted with permission from Haccompanied by exacerbation of the disease.13
Patients who discontinued budesonide treatment
had a reduced PEF (Fig. 2) and forced expiratory
volume in one second (FEV1) and increased AHR to
histamine.
In another study, a group of 10 patients with
stable asthma underwent a gradual reduction in ICS
daily dose by 200 mg at weekly intervals.14 Each
patient developed an exacerbation of symptoms on
average 16 days after the onset of steroid reduc-
tion. This loss of asthma control was accompanied
by a deterioration in FEV1, PEF and an increase in
AHR and the number of circulating eosinophils. The
deterioration in daily symptom score preceded
changes in PEF. Increasing the steroid dose induced
a reversal of each of these changes.14 Some
patients are more at risk of exacerbation than
others following a reduction in ICSs. Using a
Kaplan–Meier survival analysis Leuppi and collea-
gues15 showed that predictive markers of asthma
exacerbation during a stepwise dose reduction of
ICS were AHR to both histamine and mannitol at
baseline; AHR to mannitol during the dose-reduc-
tion phase; patients 440 years; and % sputum
eosinophils.Mortality
Assessment of mortality is a relatively crude way to
assess the efficacy of ICSs in asthma and prospec-
tive studies are almost impossible to conduct.
However, in a retrospective study Suissa and
colleagues16 used the Saskatchewan Health data-
base to form a population-based cohort of all
patients aged 5–44 years who used anti-asthma
drugs during the period 1975 to 1991. On the
basis of a continuous dose–response analysis they0 16
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es deterioration in morning peak expiratory flow (PEF) in
aahtela et al.13
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T.T. HanselS12calculated that the rate of death from asthma
decreased by 21% with each additional canister
of ICS used in the previous year. In addition, the
rate of death from asthma during the first three
months after discontinuation of ICSs was higher
compared with those patients who continued
treatment.16Dose–response studies
The aim of dose–response studies is to show an
increasing effect from low to high doses. There is
little evidence to show that the effects of ICSs are
dose-dependant, as they tend to have a fairly flat
dose–response curve. Large numbers of patients
are required to show any dose–response with ICSs.
It is also worth noting that the shape of the
dose–response curve will vary according to the
severity of asthma. Milder asthmatic patients
should be well controlled on low doses of ICSs.Budesonide
A 12 week study in 473 patients with chronic
asthma treated with budesonide showed a statisti-
cally significant dose–response effect for the mean
change from baseline for both morning PEF (Fig. 3)
and FEV1.
17 However, very little improvement was
noted upon doubling the dose of budesonide from
800 to 1600 mg. Budesonide-treated patients also
demonstrated significant reduction in asthma
symptoms and bronchodilator use compared with
placebo.17-0.4
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Figure 3 Budesonide dose–response curve: effect of
budesonide on morning peak expiratory flow (PEF) in
patients with chronic asthma (n ¼ 473). Reprinted with
permission from Busse et al.17Markers of inflammation
In patients with asthma the efficacy of ICSs in
improving lung function and symptoms and redu-
cing the frequency of exacerbations is well-docu-
mented. However, the efficacy of corticosteroids
can also be shown by examining their anti-
inflammatory effect(s). The anti-inflammatory ef-
fect(s) of corticosteroids is usually examined using
invasive sampling methods such as bronchoalveolar
lavage and bronchial biopsies, but induced sputum
and nasal lavage have also been used.
Eosinophils
According to management guidelines the dose of
ICSs is determined according to lung function and
symptoms. However, a management strategy based
on normalisation of eosinophilic inflammation has
recently been proposed.18 In a group of patients
with moderate-to-severe asthma (n ¼ 74) the
sputum eosinophil count was 63% lower and the
incidence of both severe asthma exacerbations and
hospital admissions were significantly lower in the
sputum management group than in the standard
management group.18 These benefits were
achieved without the need for additional anti-
inflammatory treatment.
Taylor and colleagues19 investigated the effects
of 14 days treatment with three doses of the novel
corticosteroid ciclesonide (50, 200 and 800 mg)
twice daily on inflammatory mediators in induced
sputum and AHR to adenosine monophosphate
(AMP) in 29 patients with mild-to-moderate allergic
asthma. Results showed a reduction in the number
of eosinophils and the concentration of eosinophilic
cationic protein in induced sputum and a dose-
dependent reduction in AHR to AMP.19 These results
indicate that in patients with mild-to-moderate
asthma, assessment of AHR to AMP may be a more
sensitive method to evaluate a dose–response
relationship of an ICS than inflammatory para-
meters in induced sputum.
Nitric oxide
NO is an exhaled marker of inflammation and
oxidative stress in asthma. Lim and colleagues20
showed that four weeks treatment with inhaled
budesonide (800mg bd) significantly reduced the
concentration of NO in the exhaled air of 14 mild
asthmatic patients with a concomitant improvement
in FEV1 and AHR, and a reduction in the number of
sputum and biopsy eosinophils. Similarly, Kharitonov
and colleagues21 showed a dose-dependent speed of
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Effectiveness of inhaled corticosteroids S13onset and cessation of action of budesonide on
exhaled NO and asthma symptoms in a parallel
group study in 28 mild asthmatic patients over 3
weeks. Treatment with 400 mg/day budesonide
reduced exhaled NO faster than 100 mg/day and
resulted in faster recovery of exhaled NO after
treatment cessation.211 2 3 4 5 6 7 
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Figure 4 Single dose fluticasone propionate (250 mg)
given 30min pre-allergen challenge is just as effective
as regular treatment for 2 weeks (250 mg bd) in prevent-
ing a reduction in forced expiratory volume in one second
(FEV1). Reprinted with permission from Parameswaran
et al.22Allergen challenge
Allergen challenge studies are a good way of
examining the effect of a single dose of ICS. After
allergen challenge the early asthmatic response
occurs between 0 and 2 h and is associated with
mast cell degranulation. The last asthmatic re-
sponse involves the recruitment of numerous
inflammatory cells and occurs 4–10 h post allergen
challenge. Parameswaran and colleagues22 com-
pared the protective effects of single and regular
doses of inhaled FP with single and regular placebo
doses on early and late asthmatic responses. They
discovered that a single dose of FP (250 mg) given
30min before allergen challenge was just as
effective as regular treatment for two weeks
(250 mg bd) in affording protection against the early
and late asthmatic response, increased AHR and
sputum eosinophilia (Fig. 4).22 Mild asthmatics
treated for 6 days with MF also demonstrated
attenuation of allergen-induced early and late
responses, AHR and sputum eosinophilia.23 A
reduction in airway responsiveness to inhaled AMP
has recently been shown within 2 h of a single
inhalation of FP (100, 250 or 1000 mg) suggesting a
rapid topical anti-inflammatory action.24 Similarly,
Gibson and colleagues25 showed that in adults with
stable asthma (n ¼ 41) a single dose of budesonide
(2400 mg) significantly reduced the number of
sputum eosinophils and induced a 2.2-fold improve-
ment in airway responsiveness to hypertonic saline
6 h after treatment. Finally, patients with mild
allergic asthma treated for 1 week with ciclesonide
(800 mg bd) had a significantly reduced early and
late asthma response compared to placebo.26
Nasal lavage model
There are considerable problems when investigat-
ing immunological events that are taking place in
the lungs. Bronchial biopsy, bronchoalveolar la-
vage, and even sputum induction all have problems
with accessibility and invasiveness. By contrast, the
nasal passages are easily accessible. With the nasal
lavage model, test agents are delivered to the
nasal mucosa by means of a spray which accuratelyadministers substances to the nose in small
volumes. The patient leans forwards, and after
allergen challenge (e.g. with grass pollen) the nose
is rinsed with warm phosphate buffered saline
(Fig. 5). Surface exudations/secretions from the
nasal mucosa are effectively sampled and collected
onto filter paper. Samples obtained from the nasal
passages can then be analysed via cytometric ELIZA
using a Luminex system. Using this system, Ed Erin
and colleagues (data on file) showed that following
allergen challenge, interleukin (IL)-4, IL5 and IL13
were elevated in nasal secretions. The highest
concentration of these TH2 cytokines occurred
6–8 h post-allergen challenge. Pre-treatment with
a single dose of budesonide (200 mg) completely
ablated these responses (Fig. 6).Conclusion
This review examined the efficacy of ICSs in a
variety of ways. Firstly, in long-term studies
(usually 1–3 years duration) comparing the efficacy
of ICSs with other agents (i.e. b-agonists or LTAs),
assessing the efficacy of ICS/LABA combinations,
determining the effect of discontinuing corticos-
teroid therapy and determining the risk of mortal-
ity; secondly in studies of shorter duration (usually
12 weeks), by examining the dose–response of
different ICSs; and finally by reviewing the effect of
single doses of corticosteroids on allergen chal-
lenge in a number of models. The results of these
studies show that ICSs are very effective in
reducing the signs and symptoms of asthma as well
as the underlying inflammatory component of the
disease. In the future, the challenge will be to
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Figure 6 Pre-treatment with a single dose of budesonide
(200 mg) ablated an allergen-induced increase in inter-
leukin (IL)-5 in the nasal lavage model. Data on file (Ed
Erin et al).
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Figure 5 Nasal lavage model.
T.T. HanselS14develop therapy that can either be added on or
used as an alternative to ICSs.References
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